(135) Not Just Fentanyl: Protracted Withdrawal from Para-Fluorofentanyl

Background & Introduction: The opioid epidemic has been exacerbated by the proliferation of synthetic opioids like para-fluorofentanyl, a potent fentanyl analog increasingly identified in illicit drug supplies [1,2]. Known for its high potency and co-occurrence with other opioids, para-fluorofentanyl has been linked to significant overdose risks and unique complications, including QT prolongation and severe withdrawal [3,4]. While studies have documented its prevalence in toxicology screenings and postmortem cases, limited research exists on its clinical management, especially during withdrawal stabilization [2,5].

Preliminary data suggest para-fluorofentanyl achieves higher brain concentrations than fentanyl, possibly explaining its enhanced toxicity and withdrawal challenges [3]. However, gaps remain regarding its pharmacodynamics and optimal treatment protocols. This case highlights the severe risks of para-fluorofentanyl use, including profound withdrawal and cardiotoxicity, while emphasizing the need for confirmatory toxicology and tailored clinical strategies. Our aim is to inform clinicians about individualized buprenorphine induction protocols that safely address withdrawal and cardiac risks in the context of synthetic opioid use.

Case Description: A 50-year-old woman with a 3-to-4-year history of smoking what she believed to be heroin was admitted to the hospital for severe opioid withdrawal and prolonged QT interval. Toxicology testing confirmed the presence of para-fluorofentanyl, a potent fentanyl analog. Two weeks prior to this admission, the patient had undergone outpatient buprenorphine induction, which was complicated by severe withdrawal symptoms, including diarrhea, electrolyte imbalances, possible seizure-like activity, and elevated cardiac troponin levels consistent with demand ischemia. An electrocardiogram (ECG) at that time revealed a markedly prolonged QT interval of 636 ms. Despite maintaining sobriety for two weeks post-discharge, she relapsed, using up to half a gram of para-fluorofentanyl daily just before this admission.

On arrival to the emergency department, the patient reported chills, goosebumps, diffuse myalgias, and anxiety but was not in overt distress. Vital signs included blood pressure of 145/78 mm Hg, heart rate of 88 beats per minute, and oxygen saturation of 99% on room air. ECG showed a prolonged QTc interval of 525 ms. Laboratory studies were notable only for mildly low magnesium (1.9 mg/dL). Given her history of severe withdrawal complications, she was admitted to a telemetry unit for close monitoring and controlled buprenorphine induction.

The patient was diagnosed with severe opioid use disorder secondary to para-fluorofentanyl, complicated by prolonged QT interval and demand ischemia. Management included telemetry monitoring, carvedilol to reduce QT prolongation risk, and magnesium repletion. A cautious buprenorphine induction protocol was initiated, starting at 2 mg and titrated to 8 mg daily over 48 hours. Despite low Clinical Opiate Withdrawal Scale (COWS) scores, her symptoms suggested significant withdrawal, which resolved with slow titration. Upon discharge, her QTc had improved to 512 ms, and withdrawal symptoms were controlled. Outpatient follow-up with cardiology and addiction medicine was arranged to monitor ongoing risks associated with para-fluorofentanyl use.

Conclusion & Discussion: This case highlights the significant risks associated with para-fluorofentanyl, including severe withdrawal symptoms and QT interval prolongation [1,2]. The primary finding is that para-fluorofentanyl complicates withdrawal management by increasing cardiac risks, necessitating close monitoring and cautious buprenorphine induction. The patient’s stabilization through telemetry, carvedilol, magnesium repletion, and individualized induction protocol emphasizes the need for tailored approaches [3].

Additional findings underline the challenges posed by synthetic opioids, which are often missed in standard toxicology screens, making advanced testing essential [4]. Para-fluorofentanyl’s heightened brain concentrations compared to fentanyl may explain its toxicity and withdrawal severity, highlighting the importance of confirmatory toxicology and clinical protocols for fentanyl analogs [3].

Limitations include the inpatient setting’s lack of generalizability and the need for further research to evaluate broader applicability. Nonetheless, this case illustrates the necessity of multidisciplinary collaboration between addiction medicine and cardiology to mitigate the risks posed by synthetic opioids. Timely research and public health interventions are critical to reducing the morbidity and mortality associated with para-fluorofentanyl and other fentanyl analogs [2,5].

References: Barrientos, R. C., et al. (2020). Novel vaccine that blunts fentanyl effects and sequesters ultrapotent fentanyl analogues. Molecular Pharmaceutics, 17(9), 3447–3458.

Bitting, J., et al. (2022). Overdose deaths involving para-fluorofentanyl. Morbidity and Mortality Weekly Report, 71(39), 1239–1240.

Canfield, J. R., & Sprague, J. E. (2024). Para-fluorofentanyl: Coincidence or intentional? Addiction, 119, 1655–1656.

Giltner, A., et al. (2022). Fentanyl analog trends in Washington D.C. Forensic Science International, 338, Article 111393.

Trecki, J., et al. (2022). Increased incidence of fentanyl-related deaths involving para-fluorofentanyl. Morbidity and Mortality Weekly Report, 71(3), 90–91.